Channel Therapeutics Corporation
CHRO
$1.12
$0.032.75%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -315.68% | 3,089.23% | |||
| Gross Profit | 315.68% | -3,089.23% | |||
| SG&A Expenses | -5.75% | -6.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.90% | 16.11% | |||
| Operating Income | 10.90% | -16.11% | |||
| Income Before Tax | -13.69% | 4.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.69% | 4.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.69% | 4.34% | |||
| EBIT | 10.90% | -16.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -9.09% | 4.63% | |||
| Normalized Basic EPS | 10.14% | -15.75% | |||
| EPS Diluted | -9.09% | 4.63% | |||
| Normalized Diluted EPS | 10.14% | -15.75% | |||
| Average Basic Shares Outstanding | 4.22% | 0.32% | |||
| Average Diluted Shares Outstanding | 4.22% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||